IDEAYA Biosciences (IDYA) said Monday it has entered into a research collaboration with ATTMOS to develop a physics-based small molecule discovery computational platform for undruggable oncology targets.
The companies will integrate expertise in structural biology, drug discovery, and computational chemistry to develop a high-throughput workflow for absolute binding free energy perturbation predictions of drug candidates.
The collaboration will use the Amber molecular dynamics suite for GPU-accelerated simulations, with IDEAYA incorporating its drug discovery data to train ABFEP-based active learning cycles for efficient small molecule screening, the company said.
Financial details weren't disclosed.
Shares of IDEAYA Biosciences were down more than 2% in recent Monday trading.
Price: 20.00, Change: -0.57, Percent Change: -2.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。